| Issue | Title | |
| Vol 2008, No 101 (2008) | Pfizer and UCB Join Forces on Drug Discovery Efforts | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2005, No 62 (2005) | Pfizer and Vicuron: A Taste of Things to Come? | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 5 (2016) | Pfizer and WAVE Collaborate to Develop Metabolic Therapies | Abstract pdf html |
| Keshav Mahawar | ||
| Vol 2016, No 1 (2016) | Pfizer Anticipates Tax Savings and Revenue Growth via US$160 B Mega-Merger with Allergan | Abstract pdf |
| Heather Cartwright, Sayani Datta, Rohit Khera & Keshav Mahawar | ||
| Vol 2013, No 4 (2013) | Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 6 (2017) | Pfizer Bolsters Anti-Infectives Presence with Basilea Deal | Abstract pdf html |
| Natasha Piper | ||
| Vol 2022, No 4 (2022) | Pfizer Bolsters RSV Pipeline with US$525 M ReViral Acquisition | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2016, No 8 (2016) | Pfizer Boosts Rare Disease Franchise through Bamboo Therapeutics Acquisition | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2005, No 61 (2005) | Pfizer Broadens Anti-Infectives Business through Acquisition of Vicuron | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 5 (2022) | Pfizer Buys Biohaven for US$11.6 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2003, No 42 (2003) | Pfizer Collaborates with Akzo Nobel over New Antipsychotic | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 8 (2021) | Pfizer Collaborates with Arvinas for Breast Cancer Therapy | Abstract pdf html |
| Shikha Kashyap | ||
| Vol 2022, No 1 (2022) | Pfizer Collaborates with Beam on Gene Editing Technology | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 8 (2012) | Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 5 (2017) | Pfizer Collaborates with Sangamo on Gene Therapy Programmes for Haemophilia A | Abstract pdf html |
| Natasha Piper | ||
| Vol 2008, No 96 (2008) | Pfizer Continues Its Biologics Focused Deal-Making | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2011, No 4 (2011) | Pfizer Continues its Pursuit of Rare Disease Therapies with Zacharon Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 1 (2017) | Pfizer Enriches Oncology Franchise Through BioInvent’s TAM Targeting Antibodies | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2011, No 8 (2011) | Pfizer Establishes Potential US$50 M Drug Discovery Pact with University of California, San Diego | Abstract |
| Heather Cartwright | ||
| Vol 2025, No 10 (2025) | Pfizer Expands Obesity Portfolio with US$4.9 B Acquisition of Metsera | Abstract pdf html |
| Shikha Kashyap | ||
| Vol 2012, No 11 (2012) | Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 103 (2008) | Pfizer Gains European Rights to Specialist Biologic Product, Xiaflex | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2019, No 3 (2019) | Pfizer Gains Option to Acquire Gene Therapy Specialist Vivet Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 12 (2101) | Pfizer Gains Phase II Skin Fibrosis Drug with Excaliard Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 66 (2005) | Pfizer Hopes for Second Time Lucky in Anti-inflammatory Drugs Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 10 (2019) | Pfizer Licenses Akcea’s AKCEA-ANGPTL3-LRx | Abstract pdf html |
| Michelle Liu | ||
| Vol 2010, No 9 (2010) | Pfizer Licenses Commercial Rights to Biocon’s Biosimilar Insulin Products | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 1 (2020) | Pfizer Licenses eFFECTOR's eIF4E Inhibitors to Bolster Oncology Pipeline | Abstract html pdf |
| Neha Madhwani | ||
| Vol 2004, No 52 (2004) | Pfizer Licenses Nitric Oxide-Donating Compounds from NicOx | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 1 (2015) | Pfizer Licenses OPKO’s Long-Acting Human Growth Hormone | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 32 (2003) | Pfizer Licenses Phase III AMD Drug from Eyetech | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 1 (2011) | Pfizer Licenses Seattle Genetics’ Antibody-Drug Conjugate Technology | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 3 (2009) | Pfizer Looks for Growth in Generics and Eyecare | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 6 (2013) | Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 8 (2014) | Pfizer Makes Significant Entry into CAR-T Field with Cellectis Pact | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 11 (2013) | Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST | Abstract |
| Heathe Cartwright | ||
| Vol 2011, No 10 (2011) | Pfizer Out-Licenses its Pan-HER Inhibitor Neratinib to Puma Biotechnology | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 12 (2014) | Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 4 (2021) | Pfizer Pledges up to US$4.4 B for Myovant’s Orgovyx | Abstract pdf html |
| Sasha Yachu & Michelle Liu | ||
| Vol 2011, No 8 (2011) | Pfizer Reinforces its Pain Relief Franchise with Deal to Buy Development Partner Icagen | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 8 (2019) | Pfizer Rescues Mylan with Upjohn Merger | Abstract html pdf |
| Michelle Liu | ||
| Vol 2016, No 6 (2016) | Pfizer Returns to Deal Making with Anacor Acquisition | Abstract pdf html |
| Rohit Khera | ||
| Vol 2006, No 68 (2006) | Pfizer Secures Rights to Exubera® from Sanofi-Aventis | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | Pfizer Sells Incontinence Drug to Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | Pfizer Sells Two of its Generics Units | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 8 (2016) | Pfizer Significantly Increases Oncology Presence with Medivation Acquisition | Abstract html pdf |
| Dan Roberts | ||
| Vol 2012, No 9 (2012) | Pfizer Signs Long-Term Generics Collaboration with Mylan in Japan | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 77 (2006) | Pfizer Steps into the Vaccines Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 4 (2010) | Pfizer Steps Up Asia-Specific Drug Discovery for Tuberculosis | Abstract |
| PharmaDeals Analyst | ||
| Vol 2010, No 6 (2010) | Pfizer Strengthens Its Position in the Injectables Market | Abstract |
| Debbie Tranter | ||
| Vol 2009, No 1 (2009) | Pfizer Swallows Wyeth - Could Spark Other Acquisitions | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2002, No 25 (2002) | Pfizer terminates pagoclone agreement with Indevus | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 3 (2023) | Pfizer to Acquire ADC Cancer Specialist Seagen for US$43 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 6 (2019) | Pfizer to Acquire Array BioPharma for Colorectal Cancer Combo | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 26 (2002) | Pfizer to Acquire Pharmacia | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | Pfizer Validates Coley Pharmaceutical's ProMune#8482; with Deal Worth US$515 M Plus | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | Pfizer's Changing Strategy | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 12 (2009) | Pfizer’s Entrance into Orphan Drugs Adds to Genzyme’s Woes | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 98 (2008) | Pfizer’s Global Strategy Begins in Asia | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2015, No 2 (2015) | Pfizer’s US$17 B Buyout of Hospira Paves the Way for a Split | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | Pharma Companies Rush to China | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 3 (2018) | Pharma Deals: Review of 2017 | Abstract pdf |
| Heather Cartwright, Natasha Piper & Taskin Ahmed | ||
| Vol 2002, No 27 (2002) | Pharmaceutical R&D Collaborations: Addressing the Productivity Problem | Abstract |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | Pharmacopeia and BMS Enter into an Alliance that Supports the Growth of Both Companies | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | Pharmacopeia Signs Two Collaborative R&D Deals | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Pharmacyclics Signs US$975 M Agreement with Janssen Biotech for Mid-Stage Btk Inhibitor | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 69 (2006) | Pharmaxis Reveals Marketing Strategy | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 1 (2017) | Pieris and Servier Collaborate on Immuno-Oncology Drug Development | Abstract pdf html |
| Natasha Piper | ||
| Vol 2023, No 5 (2023) | Pipeline Therapeutics Signs Licensing Agreement with Janssen for Investigational Neurotherapeutic, PIPE-307 | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2012, No 4 (2012) | Piramal Moves Further Away from Branded Generics with Purchase of Bayer Molecular Imaging Assets | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 54 (2004) | Playing the Decision Game | Details html |
| Fintan Walton | ||
| Vol 2004, No 50 (2004) | Plenaxis (abarelix) | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 54 (2004) | Plexxikon and Wyeth Form Collaboration for PPAR Modulators | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 48 (2004) | Pliva d.d | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | PLIVA’s Odyssey Pharmaceuticals Continues Divestment Spree | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 5 (2011) | Poker Game | Abstract jpg |
| Clive Goddard | ||
| Vol 2008, No 92 (2008) | Post Exubera#174;: Can New Life be Breathed Back into Inhaled Insulin? | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | POZEN and AstraZeneca Amend Terms of Collaboration for Pain/Inflammation Combination Product | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Pozen and Nycomed Enter into Option Agreement for NSAID Lornoxicam | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | POZEN Forgets Migraines to Collaborate with AstraZeneca | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | POZEN Partners Migraine Products with GSK and Nycomed Danmark | Abstract |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Predix Licenses S1P1 Modulators to Amgen | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Preparing to Walk Away | Details html |
| Fintan Walton | ||
| Vol 2013, No 4 (2013) | Presidio and Boehringer Ingelheim Partner to Test All-Oral Combination for HCV Genotype-1a | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 73 (2006) | Prestara (prasterone) | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 87 (2007) | Pricing and Reimbursement: Risk and Opportunity in Pharmaceutical Deal Making | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 84 (2007) | Pricing Drugs | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 85 (2007) | Private Equity Consortium Buys Out Biomet with Sweetened Offer | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 8 (2012) | Private Equity Firm Cinven Acquires Mercury Pharma from HgCapital | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 62 (2005) | Procter & Gamble to Co-Promote Novartis’ Enablex® | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 69 (2006) | Procter and Gamble: Inspiring Success | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Product Enhancement: Halozyme and Roche Link | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Product Sale and Purchase Agreements | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | Product-Specific Royalty Financing | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Products under Development and the Licensing and Due Diligence Processes | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 2 (2011) | Progenics Licenses Relistor® to Salix Outside of Japan | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 101 (2008) | Progenics Outlicenses Japanese Rights to Relistor® | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2016, No 6 (2016) | Promising AML Therapy Draws Jazz to US$1.5 B Acquisition of Celator | Abstract pdf html |
| Jasmine Kalsi & Heather Cartwright | ||
| 1901 - 2000 of 2613 Items | << < 15 16 17 18 19 20 21 22 23 24 > >> | |